Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Kirin Pharma To Close Three Of Four R&D Sites In Japan

This article was originally published in PharmAsia News

Executive Summary

Kirin Pharma of Japan says it will close all but one of its R&D sites within the next three years. The firm, a subsidiary of Kirin Holdings, has four such sites in the Gunma Prefecture employing about 200 researchers. The company said the workers would be reassigned as it sells the closing facilities. Kirin R&D work is to be done in conjunction with another subsidiary, Kyowa Hakko Kogyo, after a merger scheduled for October. (Click here for more - a subscription may be required

You may also be interested in...

Outlicensing Offers Benefits to Japanese Pharma – Aveo CEO

By outlicensing early-stage compounds, Japanese pharma can gain benefits beyond receiving licensing fees, including de-risking Japanese development, according to a U.S. biotech CEO

China Poised To Conditionally Approve First COVID Vaccine

The China National Biotec Group has filed the first application in China for the broad use of a COVID-19 vaccine, days after the national regulatory agency released review guidelines for the conditional approval of such products.

Novartis Faces Another Challenge To Entresto In India

More patent-related turbulence appears ahead for Novartis’s sacubitril/valsartan combination in India, with Torrent emerging as the new challenger. The companies are engaged in a legal battle and the Indian firm is also seeking a revocation of the patent on the star heart failure treatment.




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts